|
1
|
Mok TS, Wu YL, Thongprasert S, et al:
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N
Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitsudomi T, Morita S, Yatabe Y, et al:
Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): open label, randomized phase 3
trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
|
|
3
|
Sequist LV, Martins RG, Spigel D, et al:
First-line gefitinib in patients with advanced non-small cell lung
cancer harboring somatic EGFR mutations. J Clin Oncol.
26:2442–2449. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rosell R, Viteri S, Molina MA, et al:
Epidermal growth factor receptor tyrosine kinase inhibitors as
first-line treatment in advanced nonsmall-cell lung cancer. Curr
Opin Oncol. 22:112–120. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kimura H, Kasahara K, Kawaishi M, et al:
Detection of epidermal growth factor receptor mutations in serum as
a predictor of the response to gefitinib in patients with non-small
cell lung cancer. Clin Cancer Res. 12:3915–3921. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimura H, Fujiwara Y, Sone T, et al: High
sensitivity detection of epidermal growth factor receptor mutations
in the pleural effusion of non-small cell lung cancer patients.
Cancer Sci. 97:642–648. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Molina-Vila MA, Bertran-Alamillo J,
Reguart N, et al: A sensitive method for detecting EGFR mutations
in non-small cell lung cancer samples with few tumor cells. J
Thorac Oncol. 3:1224–1235. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cohen V, Agulnik JS, Ang C, et al:
Epidermal growth factor receptor mutations detected by denaturing
high-performance liquid chromatography in nonsmall cell lung
cancer. Cancer. 111:4309–4317. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim HJ, Lee KY, Kim YC, et al: Detection
and comparison of peptide nucleic acid-mediated real-time
polymerase chain reaction clamping and direct gene sequencing for
epidermal growth factor receptor mutations in patients with
non-small cell lung cancer. Lung Cancer. 75:321–325. 2012.
View Article : Google Scholar
|
|
10
|
Lee KY, Kim HJ, Kim SJ, et al:
PNA-Mediated PCR Clamping for the detection of EGFR mutations in
non-small cell lung cancer. Tuberc Respir Dis. 69:271–278. 2010.
View Article : Google Scholar
|
|
11
|
Kim HJ, Kim WS, Shin KC, et al:
Comparative analysis of peptide nucleic acid (PNA)-mediated
real-time PCR clamping and DNA direct sequencing for EGFR mutation
detection. Tuberc Respir Dis. 70:21–27. 2011. View Article : Google Scholar
|
|
12
|
Pao W and Ladanyi M: Epidermal growth
factor receptor mutation testing in lung cancer, searching for the
ideal method. Clin Cancer Res. 13:4954–4955. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Langaee T and Ronaghi M: Genetic variation
analyses by pyrosequencing. Mutat Res. 573:96–102. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ahmadian A, Ehn M and Hober S:
Pyrosequencing: history, biochemistry and future. Clin Chim Acta.
363:83–94. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dufort S, Richard MJ and Fraipont F:
Pyrosequencing method to detect KRAS mutation in formalin-fixed and
paraffin-embedded tumor tissues. Anal Biochem. 391:166–168. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tsiatis AC, Norris-Kirby A, Rich RG, et
al: Comparison of Sanger sequencing, pyrosequencing and melting
curve analysis for the detection of KRAS mutations. J Mol Diagn.
12:425–432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim SK, Kim DL, Han HS, et al:
Pyrosequencing analysis for detection of a BRAFV600E mutation in an
FNAB specimen of thyroid nodules. Diagn Mol Pathol. 17:118–125.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inoue A, Kobayashi K, Usui K, et al:
First-line gefitinib for patients with advanced non-small cell lung
cancer harboring epidermal growth factor receptor mutations without
indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maemondo M, Inoue A, Kobayashi K, et al:
Gefitinib or chemotherapy for non-small-cell lung cancer with
mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ettinger DS, Akerley W, Bepler G, et al:
Non-small cell lung cancer. J Natl Compr Canc Netw. 8:740–801.
2010.PubMed/NCBI
|
|
21
|
Pirker R, Herth FJ, Kerr KM, et al:
Consensus for EGFR mutation testing in non-small cell lung cancer:
results from a European workshop. J Thorac Oncol. 5:1706–1713.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ronaghi M: Pyrosequencing sheds light on
DNA sequencing. Genome Res. 11:3–11. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ogino S, Kawasaki T, Brahmandam M, et al:
Sensitive sequencing method for KRAS mutation detection by
pyrosequencing. J Mol Diagn. 7:413–421. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Uhlmann K, Brinckmann A, Toliat MR, et al:
Evaluation of a potential epigenetic biomarker by quantitative
methyl-single nucleotide polymorphism analysis. Electrophoresis.
23:4072–4079. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tost J, Dunker J and Gut IG: Analysis and
quantification of multiple methylation variable positions in CpG
islands by pyrosequencing. Biotechniques. 35:152–156.
2003.PubMed/NCBI
|
|
26
|
Forbes SA, Bharma G, Bamford S, et al: The
catalogue of somatic mutations in cancer (COSMIC). Curr Protoc Hum
Genet Chapter 10: unit 10.11. 2008. View Article : Google Scholar
|
|
27
|
Rekhtman N, Brandt SM, Sigel CS, et al:
Suitability of thoracic cytology for new therapeutic paradigms in
non-small cell lung carcinoma: High accuracy of tumor subtyping and
feasibility of EGR and KRAS molecular testing. J Thor Oncol.
6:451–458. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tokumo M, Toyooka S, Kiura K, et al: The
relationship between epidermal growth factor receptor mutations and
clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
29
|
Shigematsu H, Lim L, Takahashi T, et al:
Clinical and biological features associated with epidermal growth
factor receptor gene mutations in lung cancers. J Natl Cancer Inst.
97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
